Protocol Section List

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Protocol Section List
You are on Page 2550 of 2568:
2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560

Protocol Sections: The Identification Through IPD Sharing Statement are Modules For This Protocol Section

NCTID Brief Title Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Oversight Description Conditions View
NCT00004288 Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004287 Phase I Study of the Third Generation Adenovirus H5001CBCFTR in Patients With Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004286 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004285 Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004284 Phase III Randomized Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004278 Phase III Randomized Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004276 Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004275 Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turners Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004274 Effect of Estrogen on Mental and Social Functioning in Girls With Turners Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004268 Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004266 Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004265 Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004264 Docetaxel Cisplatin and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004263 Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004262 Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004261 EF5 Prior to Surgery or Biopsy in Patients With Breast Prostate or Cervical Cancer or High Grade Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004260 Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004259 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004258 EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004257 Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004256 Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004255 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004254 Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004253 Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004252 Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004251 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004250 Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004249 Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004248 Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004246 Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth Pharynx or Larynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004245 Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome Acute Myelogenous Leukemia or Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004244 Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004243 Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004242 Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer Malignant Lymphoma or Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004239 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004238 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004237 Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004236 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004235 Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004234 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth Pharynx or Larynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004233 S9915 Triacetyluridine Fluorouracil and Leucovorin in Treating Patients With Unresectable Locally Advanced or Metastatic Cancer of the Esophagus or Stomach Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004232 Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004231 Combination Chemotherapy Bone Marrow or Peripheral Stem Cell Transplantation andor Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004230 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004229 Endostatin in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004228 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004227 Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx Hypopharynx or Larynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004226 Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004225 Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004224 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004223 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004221 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004220 Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004219 Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004218 Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004217 S9918 PSC 833 Daunorubicin and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004216 VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004215 Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004213 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004212 DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004211 Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004210 Study of the Results of Education and Counseling for Persons Undergoing Genetic Testing for Hereditary Nonpolyposis Colon Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004209 Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004208 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004207 Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004206 Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004205 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004204 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004203 Oxaliplatin in Treating Patients With Metastatic Bladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004202 Combination Chemotherapy Radiation Therapy and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004201 Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB Stage IV or Recurrent Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004200 Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004199 Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004198 Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004197 Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004196 Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004195 Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004194 Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004193 ISIS 2503 in Treating Patients With Metastatic andor Locally Recurrent Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004192 Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004190 Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004189 Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004188 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004187 Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004186 Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004184 Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004183 Capecitabine in Treating Patients With Malignant Mesothelioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004182 Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004181 Bone Marrow Transplantation in Treating Patients With Multiple Myeloma Chronic Phase Chronic Myelogenous Leukemia or Agnogenic Myeloid Metaplasia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004180 Rosiglitazone in Treating Patients With Liposarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004179 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004178 Gene Therapy in Treating Patients With Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004177 Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004176 Amifostine Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004175 Docetaxel Doxorubicin and Cyclophosphamide in Treating Women With Stage III Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004174 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004173 Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004172 Chemotherapy Filgrastim and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004171 Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkins Disease or Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004169 Chemotherapy Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkins Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004166 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004165 Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004164 Combination Chemotherapy in Treating Patients With Stage IIB Stage III or Stage IV Cancer of the Nasopharynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004163 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004162 Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004161 Fenretinide in Treating Patients With Leukoplakia of the Mouth Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004160 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004159 Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004158 Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004157 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkins Lymphoma Hodgkins Disease Breast Cancer or Other Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004156 Vaccine Therapy in Treating Patients With Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004154 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004153 Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004152 PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004151 Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004150 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004149 Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004148 Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004147 COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004146 Carboxyamidotriazole RT in Treating Patients Newly Diagnosed Supratentorial GBM Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004145 Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004144 Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004143 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies Bone Marrow Failure Syndromes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004142 Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004141 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004139 Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004138 Positron Emission Tomography for Detecting Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004137 S9914 Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004136 Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004135 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004132 Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004129 Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004128 Combination Chemotherapy Interleukin-2 and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004127 Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004126 Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004125 Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004124 S9921 Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004123 Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004122 BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004115 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004114 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004113 Temozolomide in Treating Patients With Recurrent Malignant Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004112 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004110 Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004109 Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004108 DX-8951f in Treating Patients With Liver Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004107 Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstroms Macroglobulinemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004106 Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004105 Combination Chemotherapy in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004104 Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004103 Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004102 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004101 Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004100 Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004099 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004097 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced andor Recurrent Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004096 Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004095 Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004094 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth Pharynx or Larynx Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004093 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004092 Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004091 Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004090 Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004089 Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004088 Combination Chemo Peripheral Stem Cell Transplant Biological Therapy Pamidronate and Thalidomide for Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004087 Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004086 Radiolabeled Monoclonal Antibody Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004085 Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004084 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004083 Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004082 Combination Chemotherapy in Treating Patients With Previously Untreated Newly Diagnosed Epithelial Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004081 Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004080 Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004079 Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004078 Irinotecan in Treating Children With Refractory Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004077 Paclitaxel Ifosfamide and Cisplatin in Treating Patients With Metastatic Testicular Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004076 PNU 166148 in Treating Patients With Metastatic Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004075 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004074 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2Neu Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004073 Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004072 O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004071 Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004070 Gene Therapy in Treating Patients With Unresectable Recurrent or Refractory Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004068 Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004067 Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004066 Gemcitabine Docetaxel and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004065 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004064 Monoclonal Antibody Therapy in Treating Patients With Ovarian Fallopian Tube or Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004063 Cisplatin Gemcitabine Interferon Alfa and Hyperthermia in Treating Patients With Advanced Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004062 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004061 Biological Therapy in Treating Patients Undergoing Radiation Therapy Chemotherapy and Peripheral Stem Cell Transplantation for Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004060 Chemotherapy in Treating Patients With Recurrent Metastatic or Unresectable Ovarian Fallopian Tube or Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004059 Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004058 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004057 Paclitaxel Plus L-778123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004056 Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004055 Topotecan Paclitaxel and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004054 Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00004052 Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View